Sage Therapeutics Inc
NASDAQ:SAGE 3:59:59 PM EDT
Market Cap (Intraday) | 4.86B |
Current PE | N/A |
Forward PE | N/A |
2yr Forward PE | N/A |
10-Day MA | $82.54 |
50-Day MA | $84.68 |
200-Day MA | $62.24 |
SAGE Therapeutics, Inc. Stock, NASDAQ:SAGE
215 1st Street, Cambridge, Massachusetts 02142
United States of America
Phone: +1.617.299.8380
Number of Employees: 675
Description
SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey on April 16, 2010 and is headquartered in Cambridge, MA.